HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health

HMI-115 demonstrates statistically significant improvement of endometriosis-related pain Dysmenorrhea NRS scores decreased by 41.57%, 34.72%, and 27.35% across the three dosage groups Non-menstrual pelvic pain NRS scores decreased across all HMI-115 dosage groups, with sustained efficacy...